Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor T Gavrilovic

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Seminars in Neurology|February 4, 2010
Pearls: primary brain tumorsCraig Nolan, Igor T Gavrilovic
Current Oncology Reports|December 22, 2004
Diagnosis and treatment of primary central nervous system lymphomaIgor T Gavrilovic, Lauren E Abrey
Current Oncology Reports|August 5, 2004
Primary central nervous system lymphomaIgor T Gavrilovic, Lauren E Abrey
Journal of Neuro-Oncology|October 11, 2005
Brain metastases: epidemiology and pathophysiologyIgor T Gavrilovic, Jerome B Posner
Journal of Neuro-Oncology|June 9, 2012
Temozolomide or bevacizumab for spinal cord high-grade gliomasThomas J Kaley, Ijah Mondesire-Crump, Igor T Gavrilovic
Journal of Neuro-Oncology|August 22, 2019
Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomasPrakirthi Yerram, Samantha N Reiss, Lisa Modelevsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphomaIgor T Gavrilovic, Adília Hormigo, Joachim Yahalom, et al.
Neuro-Oncology Practice|May 3, 2019
Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhageXuling Lin, Mariza Daras, Elena Pentsova, et al.
Journal of Neuro-Oncology|June 28, 2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomasGaurav D Shah, Joel S Silver, Steven S Rosenfeld, et al.
The Oncologist|January 28, 2012
Characteristics of oral mucosal events related to bevacizumab treatmentIgor T Gavrilovic, Yevgeniy Balagula, Alyx C Rosen, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Seminars in Neurology|February 4, 2010
Pearls: primary brain tumorsCraig Nolan, Igor T Gavrilovic
Current Oncology Reports|December 22, 2004
Diagnosis and treatment of primary central nervous system lymphomaIgor T Gavrilovic, Lauren E Abrey
Current Oncology Reports|August 5, 2004
Primary central nervous system lymphomaIgor T Gavrilovic, Lauren E Abrey
Journal of Neuro-Oncology|October 11, 2005
Brain metastases: epidemiology and pathophysiologyIgor T Gavrilovic, Jerome B Posner
Journal of Neuro-Oncology|June 9, 2012
Temozolomide or bevacizumab for spinal cord high-grade gliomasThomas J Kaley, Ijah Mondesire-Crump, Igor T Gavrilovic
Journal of Neuro-Oncology|August 22, 2019
Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomasPrakirthi Yerram, Samantha N Reiss, Lisa Modelevsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphomaIgor T Gavrilovic, Adília Hormigo, Joachim Yahalom, et al.
Neuro-Oncology Practice|May 3, 2019
Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhageXuling Lin, Mariza Daras, Elena Pentsova, et al.
Journal of Neuro-Oncology|June 28, 2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomasGaurav D Shah, Joel S Silver, Steven S Rosenfeld, et al.
The Oncologist|January 28, 2012
Characteristics of oral mucosal events related to bevacizumab treatmentIgor T Gavrilovic, Yevgeniy Balagula, Alyx C Rosen, et al.
Pageof 3